China's pharmaceutical industry will enter the high-end level, official interpretation of the 13th five year plan

Source: Biovalley 2016-06-23 from the early days of the people's Republic of China to now, the pharmaceutical industry has slowly developed from the initial level to today's medium and high-end level Although it has made remarkable progress, it still lingers in the middle level for many years Ren Dequan, former deputy director of the State Food and drug administration, said yesterday that China's pharmaceutical industry is about to enter the high-end level and become an international pharmaceutical power What are the reasons for wandering in the middle end for many years? In the past 20 years, China has been hovering in the middle level, whether from the supplier, the recipient, or even the government environment, there may be some deficiencies Next, Director Ren Dequan reviewed the past and combined with the future, analyzed four main reasons that restricted us from jumping out of the middle level In the past, the main reasons that restricted us from jumping out of the middle level were as follows: 1 Although China's pharmaceutical industry has been in the international middle level since the 1990s, and has made progress in recent years, the industrial bodies of more than 5000 enterprises are still small and scattered, most of them are not high-level, and the situation of large but not strong industries has basically not changed 2 The mechanism of "supporting medicine with medicine" is an important reason for the long-term wandering of the pharmaceutical industry The terminal of China's medical market is mainly in hospitals Under the mechanism of "medical support by drugs", drugs become the carrier of income generation, which leads to the behavior distortion of "hospital drug intake, doctor drug use" 3 The lag of drug price reform also restricts the survival of the fittest The government's price limit management of the highest retail price has brought some "false high drug prices" 4 Drug supervision is weak and elimination is weak Drug supervision is weak, coupled with the internal problems of its own system, lack of supervision, resulting in some enterprises can not be punished and eliminated Although the platform needed to cross the barriers is facing many difficulties, we still have the opportunity to grow Maybe in the difficulties, we are more likely to Nirvana and rebirth In recent years, pharmaceutical enterprises have also been following the international pace to continuously improve their research technology, cultivate special talents, prepare for the sprint, and make achievements little by little Ren Dequan is full of hope for the industry and analyzes the current advantages of China's pharmaceutical industry in detail China has formed the basic conditions to move towards high-end level: 1 In the past 20 years, the level of production technology and scale of API in China has continued to rise At present, many bulk APIs have become the world's production countries At the same time, special new APIs with expired patents have also been developed and listed, and the categories are constantly enriched Chinese enterprises have obtained more than 1400 kinds of DMF record varieties in the United States, and the export scale has increased nearly 10 times 2 At the same time, pharmaceutical preparations have made significant progress in the production environment, facilities, machinery, auxiliary materials and packaging and other basic conditions, and the products of local leading enterprises basically meet the international requirements In 2004, GMP was fully implemented in China, and now more than 50 enterprises have passed the certification of the United States, the European Union, Japan and who 3 In the research and development of innovative drugs, not only a batch of innovative drugs have been listed successively, such as buthenol, exetane, apatinib, xidaban and desetabin, but also pharmaceutical enterprises, such as Hengrui, Shiyao, Xiansheng, Beida and MICROCORE biology, which have been committed to the research and development of innovative drugs, have emerged 4 In terms of innovative R & D talents, both those who have returned from abroad and those who have been trained locally have taken shape 5 China's unique resources of traditional Chinese medicine, a number of modern important clinical validation in the United States and Europe, China's traditional Chinese medicine will go to the world The original intention and task of formulating the 13th five year plan in the face of such a fierce pharmaceutical market, coupled with the aging population and the comprehensive development of the second child in China, China has to adjust its strategic plan to transform from a pharmaceutical power to a pharmaceutical power The 12th Five Year Plan for the pharmaceutical industry and the previous plans were independently prepared by the Ministry of industry and information technology, while the 13th five year plan for the pharmaceutical industry was jointly prepared by the Ministry of industry and information technology, together with the development and Reform Commission, the Ministry of science and technology, the Ministry of Commerce, the Health Planning Commission and the food and drug administration "Wu Haidong, deputy director of the Department of consumer goods of the Ministry of industry and information technology, said to see the government's attention to the development of the pharmaceutical industry this time With the efforts of all parties, the demand of the pharmaceutical market has been growing steadily, and obvious technological progress has been made The industrial policy and the medical reform policy have been continuously improved, and the industry supervision has been continuously strengthened, and the overall opportunity is greater than the challenge The next goal is to achieve: the average annual growth rate of the industry scale is higher than 10%; the R & D intensity reaches 2%; GMP certification enterprises reach 100: strengthen green development, reduce energy consumption by 10% and water consumption by 23%; MES utilization rate reaches 30%; clinically urgent patent expired drugs are basically imitated and listed; the top 100 enterprises increase business revenue by 10%; export delivery value accounts for sales revenue The proportion reaches 10% If we want to meet the above requirements, we need to complete the following eight tasks: 1 Enhance the ability of industrial innovation; 2 Improve the level of quality and safety; 3 Improve the ability of supply guarantee; 4 Promote the green transformation and upgrading; 5 Promote the deep integration of the two modernizations; 6 Optimize the industrial organization structure; 7 Improve the level of international development; 8、 Expand new areas and develop new formats With the development of the times, the reform of the medical industry, and the improvement of people's education level, it is now the stage of cultivating new healthy consumption demand It has become a new market demand direction to promote the development of household, pension and rehabilitation medical devices and develop large-scale health products We must vigorously promote the "Internet plus medicine" and launch mobile medical products and wearable devices that have cloud services and artificial intelligence functions, so as to meet the needs of modern people for medical services Based on the current industry progress, government promotion and market environment, China's entry into the high-end level is just around the corner